Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H27N5O3.ClH |
Molecular Weight | 409.91 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2
InChI
InChIKey=NBGBEUITCPENLJ-UHFFFAOYSA-N
InChI=1S/C19H27N5O3.ClH/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19;/h11-12H,4-10H2,1-3H3,(H2,20,21,22);1H
DescriptionSources: http://www.e-search.ne.jp/~jpr/PDF/EISAI03.PDFCurator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1988.tb00517.x | https://medikamio.com/de-de/medikamente/andante-3mg/pil | doi: 10.1016/B978-008055232-3.61351-0 | http://adisinsight.springer.com/drugs/800004823
Sources: http://www.e-search.ne.jp/~jpr/PDF/EISAI03.PDF
Curator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1988.tb00517.x | https://medikamio.com/de-de/medikamente/andante-3mg/pil | doi: 10.1016/B978-008055232-3.61351-0 | http://adisinsight.springer.com/drugs/800004823
Bunazosin (E-643) is a quinazoline derivative with a1-adrenoceptor blocking activity. It has been clinically used both as a systemic antihypertensive as well as an ocular hypotensive drug. The major adverse effect associated with the use of bunazosin is orthostatic hypotension or its consequences (e.g. dizziness). Others adverse effects include headache, sweating, nausea, dry mouth, abdominal pain, diarrhea, and constipation. The effects of Bunazosin may be enhanced by diuretics and other antihypertensive agents and decreased by Rifampicin.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907610 Sources: http://www.e-search.ne.jp/~jpr/PDF/EISAI03.PDF |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Detantol@R Approved UseDetantol is indicated to treat hypertension. |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. | 2002 Jan |
|
Amelioration by topical bunazosin hydrochloride of the impairment in ocular blood flow caused by nitric oxide synthase inhibition in rabbits. | 2003 Feb |
|
[Effects of ocular hypotensive agents on the circadian rhythm in intraocular pressure in rabbits as measured by telemetry]. | 2003 Sep |
|
Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma. | 2003 Sep-Oct |
|
Alterations of alpha-adrenergic modulations of coronary microvascular tone in dogs with heart failure. | 2005 Jun |
|
An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. | 2006 Oct |
|
[Case of pigmentary glaucoma treated with medical therapy, laser treatment, and trabeculotomy]. | 2007 Feb |
|
New perspectives of infections in cardiovascular disease. | 2009 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.e-search.ne.jp/~jpr/PDF/EISAI03.PDF
3 to 9 mg once daily. The administration should be started
at a dose of 3 mg once daily and the maximum daily dose of 9 mg should not be exceeded.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL188185
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
100000084835
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
18V54TZ7U6
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
SUB00899MIG
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
DTXSID7048588
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
C77301
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
115305
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
DBSALT002161
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
C018176
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
52712-76-2
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | |||
|
m2761
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
236888
Created by
admin on Fri Dec 15 16:20:05 GMT 2023 , Edited by admin on Fri Dec 15 16:20:05 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SUBSTANCE RECORD